BIOFORCE NANOSCIENCES HOLDINGS, INC. reported a net loss of $(102,411) for the three months ended March 31, 2026, a substantial improvement from a net loss of $(935,457) in the prior year period, partly due to a $15,322 legal settlement. Despite the improved financial performance, the company continues to face recurring losses and has a going concern issue with zero sales. In a significant corporate action, director Merle Ferguson sold his controlling 80% stock interest to Nexus Capital Investments, Inc. and forgave all his accrued compensation and other amounts due.
